2nd Quarter - Report

VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
—
Expenses
$310,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).

LobbyistCovered position, as disclosed
SCOTT BARNES —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).

LobbyistCovered position, as disclosed
SCOTT BARNES —
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Health Issues HCR

Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "FAIR Drug Pricing Act," and S. 1895: "Lower Health Care Costs Act").

LobbyistCovered position, as disclosed
SCOTT BARNES —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 2296 (116th), H.R. 2113 (116th), S. 1895 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.